Paris: Sanofi has announced that the AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately ...

Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab.

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Last week, Sanofi and Regeneron reported the failure of a phase 3 trial of their chronic obstructive pulmonary disorder (COPD) candidate itepekimab. In February, Sanofi revealed a phase 3 trial of ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Sanofi said this morning that its pipeline ... an IRAK4 degrader for atopic dermatitis, IL-33 inhibitor itepekimab for chronic obstructive pulmonary disease (COPD), and vaccines against acne ...

Sanofi also said today that it is expanding ... Meanwhile, the clinical trial programme for IL-33 inhibitor itepekimab is being expanded into CRSwNP, along with COPD and bronchiectasis.